Palbociclib (Ibrance)
A CDK4/6 inhibitor used with endocrine therapy for hormone receptor-positive, HER2-negative advanced and metastatic breast cancer.
What is Palbociclib?
What it targets
The CDK4 and CDK6 enzymes that drive the cell cycle. Blocking them stops hormone-driven breast cancer cells from dividing and helps endocrine therapy work better.
Who it may help
Adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who are candidates for endocrine-based treatment, in the first line or after prior endocrine therapy.
Why testing matters
ER, PR, and HER2 testing confirm the cancer is hormone receptor-positive and HER2-negative. Blood counts and organ function are checked before and during treatment for safety.
Which cancers can Palbociclib treat?
Palbociclib is used for hormone receptor-positive, HER2-negative breast cancer, usually combined with endocrine therapy.
| HR-positive, HER2-negative advanced breast cancer (first line) | Used with an aromatase inhibitor such as letrozole as the initial endocrine-based therapy for advanced or metastatic disease, supported by the PALOMA-2 trial. |
| HR-positive, HER2-negative breast cancer after prior endocrine therapy | Used with fulvestrant when the cancer has progressed after earlier endocrine therapy, supported by the PALOMA-3 trial. |
| Pre- or perimenopausal women | Combined with endocrine therapy plus ovarian suppression (an LHRH agonist) so that hormone-driven growth signals are controlled alongside palbociclib. |
| Endocrine-resistant, PIK3CA-mutated advanced breast cancer | Some current US labelling includes palbociclib in a triplet with inavolisib and fulvestrant for selected PIK3CA-mutated disease detected by an approved test, based on the INAVO120 trial. Eligibility must be confirmed. |
| Early-stage breast cancer (not used) | Palbociclib is not approved after surgery for early breast cancer, because the PALLAS and PENELOPE-B trials did not show benefit. Abemaciclib is the CDK4/6 inhibitor used in selected high-risk early disease. |
Are you eligible for Palbociclib?
Eligibility depends on the breast cancer subtype, the treatment setting, organ function, and blood counts.
- Confirmed hormone receptor-positive, HER2-negative breast cancer on ER, PR, and HER2 testing
- Advanced or metastatic disease, in the first line or after prior endocrine therapy
- Suitable for endocrine therapy such as an aromatase inhibitor or fulvestrant
- Adequate neutrophil and overall blood counts before starting
- Adequate liver and kidney function for the chosen regimen
- Ovarian suppression planned alongside endocrine therapy if pre- or perimenopausal
- No active serious infection at the time of starting treatment
- No severe allergy to palbociclib or its capsule or tablet components
How does Palbociclib work?
- Targeting the cell cycle
- Blocking CDK4 and CDK6
- Working with endocrine therapy
- Delaying progression
Palbociclib was the first CDK4/6 inhibitor approved for breast cancer and helped establish this drug class as a standard partner for endocrine therapy.
Tests required before starting Palbociclib
These tests confirm the breast cancer subtype, establish baselines, and check that treatment is safe to begin.
| Biopsy and histopathology | Confirms the diagnosis of breast cancer and the tumour type. |
| ER, PR, and HER2 testing | Confirms hormone receptor-positive, HER2-negative status, which is required for palbociclib. |
| Staging imaging (CT, PET-CT, MRI, or bone scan) | Defines whether the disease is advanced or metastatic and where it has spread. |
| Complete blood count (CBC) | Baseline neutrophils, white cells, red cells, and platelets, monitored closely because palbociclib commonly lowers counts. |
| Liver and kidney function tests | Assess organ function and guide dosing and monitoring. |
| Pregnancy test where relevant | Needed before starting because palbociclib can harm a developing baby. |
| PIK3CA testing (selected cases) | Done only if a biomarker-defined regimen such as the inavolisib triplet is being considered. |
How is Palbociclib given?
Palbociclib is an oral medicine taken at home, on a cycle, alongside endocrine therapy and with regular blood monitoring.
| Dosage — standard schedule | Usually taken once daily for 21 days, followed by 7 days off, making a 28-day cycle. Your oncologist sets the exact dose. |
| How to take it | Swallowed whole as a capsule or tablet. The capsule form is taken with food; follow the specific instructions for your formulation. |
| Combination partner | Almost always taken with an aromatase inhibitor such as letrozole, or with fulvestrant, plus ovarian suppression if pre-menopausal. |
| Timing | Take at about the same time each day to keep levels steady, and avoid grapefruit and grapefruit juice. |
| Missed dose | If you miss a dose or vomit, do not take an extra dose. Skip it and take the next dose at your usual time, and tell your team. |
| Duration | Continues in repeated cycles for as long as it controls the cancer and side effects stay manageable. |
Clinical evidence and benefits
Adding palbociclib to endocrine therapy has improved disease control in hormone receptor-positive, HER2-negative advanced breast cancer across large trials.
| Longer disease control in the first line | In the PALOMA-2 trial, palbociclib added to letrozole substantially delayed disease progression compared with letrozole alone in advanced disease. |
| Benefit after prior endocrine therapy | In the PALOMA-3 trial, palbociclib added to fulvestrant significantly improved progression-free survival in patients whose disease had progressed on earlier endocrine therapy. |
| Added benefit in PIK3CA-mutated disease | In the INAVO120 trial, adding inavolisib to palbociclib and fulvestrant improved outcomes in selected endocrine-resistant, PIK3CA-mutated advanced disease. |
| An oral, non-chemotherapy option | Palbociclib offers a targeted oral treatment that can delay the need for chemotherapy in many patients with this breast cancer subtype. |
| Generally manageable outpatient treatment | Most patients take palbociclib at home with regular blood checks, and side effects are usually monitored and managed without hospital admission. |
Individual responses vary with tumour biology, disease burden, prior treatment, menopausal status, and the endocrine partner used. These reflect published clinical trial data.
Side effects of Palbociclib
Palbociclib is generally manageable, but side effects are common and are monitored closely, especially blood counts. Many are mild and improve with dose adjustment.
| Low neutrophil count (neutropenia) | The most common effect; usually without symptoms but raises infection risk. Counts are checked before each cycle and doses adjusted if needed. |
| Low white blood cells | Common; monitored through routine blood tests and managed with dose changes when required. |
| Fatigue | Frequent — usually mild to moderate and often improves over time. |
| Infections | More likely because of low white cells; report fever, sore throat, cough, or burning urination promptly. |
| Nausea and reduced appetite | Usually mild and manageable with supportive medication and small frequent meals. |
| Diarrhoea or mouth sores | Can occur; managed with diet, mouth care, and medication if needed. |
| Low red cells or platelets | Anaemia or low platelets can occur; monitored through blood tests and managed as needed. |
| Hair thinning | Mild thinning can happen, but heavy hair loss is uncommon compared with chemotherapy. |
| Abnormal liver blood tests | Liver enzymes can rise in some patients; checked through routine blood tests. |
Contact your doctor immediately if you develop:
- Fever, chills, sore throat, or any other sign of infection
- New or worsening cough, chest pain, or breathlessness
- Unusual bruising, bleeding, or extreme tiredness and pallor
- Yellowing of the eyes or skin, or dark urine
- Severe weakness, dizziness, or fainting
Safety precautions and key warnings
Tell your oncologist and pharmacist about your full medical history and every medicine, supplement, and herbal product before starting palbociclib.
- Palbociclib interacts with CYP3A drugs — strong inhibitors raise its levels and strong inducers lower them, so the team may adjust treatment
- Avoid grapefruit and grapefruit juice, which can increase palbociclib levels
- Tell your team about St John's Wort and other herbal products, which can reduce how well palbociclib works
- Report any fever or signs of infection promptly because of the risk of low white blood cells
- Tell your team about lung disease or breathing problems, as rare serious lung inflammation has been reported with this drug class
- Pregnancy should be avoided; discuss effective contraception during and for a period after treatment
- Do not breastfeed during treatment; discuss timing with your oncologist
Palbociclib combination treatments
Palbociclib is not used alone. It is combined with endocrine therapy, and in selected cases with a targeted drug, to control the cancer more effectively.
| Palbociclib + aromatase inhibitor (letrozole) | First-line treatment for HR-positive, HER2-negative advanced disease, supported by the PALOMA-2 trial. |
| Palbociclib + fulvestrant | Used when the cancer has progressed after earlier endocrine therapy, supported by the PALOMA-3 trial. |
| Palbociclib + endocrine therapy + ovarian suppression | For pre- or perimenopausal women, an LHRH agonist is added to suppress ovarian hormone production. |
| Palbociclib + inavolisib + fulvestrant | A triplet for selected endocrine-resistant, PIK3CA-mutated advanced disease, based on the INAVO120 trial; requires biomarker confirmation. |
| Switching or next-line therapy | If palbociclib combinations stop working, options include different endocrine or targeted therapy, antibody-drug conjugates, chemotherapy, or a clinical trial. |
If Palbociclib stops working
Hormone receptor-positive breast cancer can become resistant over time. Understanding why helps guide the next step.
| Endocrine resistance pathways | Changes such as ESR1 mutations can make the cancer less responsive to hormone therapy, which affects which endocrine partner is used next. |
| Cell-cycle escape | Cancer cells can find ways around CDK4/6 blockade over time, which is one reason combinations and later targeted drugs are used. |
| Re-testing at progression | Scans are repeated and new biomarker testing, such as ESR1, PIK3CA, or BRCA on blood or tissue, may guide the next treatment. |
| Next-line options | These can include a different endocrine therapy, a PI3K or AKT inhibitor, an mTOR inhibitor, a PARP inhibitor, an antibody-drug conjugate, chemotherapy, or a clinical trial. |
| Supportive care | Management of bone disease, pain, and overall wellbeing continues alongside any change in therapy. |
Cost of Palbociclib by country
Palbociclib cost depends on whether a generic or branded version is used, the dose, the number of cycles, the endocrine partner, monitoring tests, and insurance. Always ask for a full written estimate.
| India | Branded Ibrance and approved generic palbociclib are both used, and generics have improved affordability. Price varies by brand, city, and pharmacy — ask for a per-cycle estimate and any patient-support options. |
| China | Branded and approved generic palbociclib are used in leading cancer hospitals; access and price depend on hospital procurement and insurance category. CancerFax can help check practical access. |
| USA | High list price without insurance; most patients are covered through insurance, and manufacturer patient-assistance programmes may apply for eligible patients. |
| UK / Europe | Available through national health systems for approved indications, usually with low out-of-pocket cost for covered patients; self-pay costs are substantial. |
Availability of Palbociclib globally
Palbociclib is available in many major markets, though brand, formulation, and generic options vary by country and hospital.
India
Available at major cancer centres for HR-positive, HER2-negative advanced breast cancer, with branded and approved generic options. CancerFax can help check access and second-opinion pathways.
China
Used in leading cancer hospitals, with NMPA-approved branded and generic palbociclib. Access depends on hospital procurement and insurance category.
USA
FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer with endocrine therapy, and as part of a triplet for selected PIK3CA-mutated disease.
Europe
Authorised across the European Union for HR-positive, HER2-negative advanced breast cancer with endocrine therapy, and covered by national health systems for approved indications.
Palbociclib in current clinical trials
Research continues into how palbociclib is best sequenced, combined, and matched to the right patients in HR-positive breast cancer.
| Sequencing after CDK4/6 inhibitors | Studies of what works best after first-line CDK4/6 inhibitor therapy, including next-generation endocrine and targeted drugs. |
| New combinations | Trials testing palbociclib with PI3K, AKT, and other pathway inhibitors and with oral selective estrogen receptor degraders (SERDs). |
| Biomarker and real-world studies | Research, including Indian real-world data, into which patients benefit most and how palbociclib performs outside clinical trials. |
Your treatment journey with Palbociclib
Diagnosis and receptor testing
Staging and treatment planning
Baseline safety checks
Starting treatment
Monitoring and response assessment
Continuing or changing therapy
Questions to ask your oncologist about Palbociclib
- Is my breast cancer hormone receptor-positive and HER2-negative?
- Will I take Palbociclib with letrozole or with fulvestrant?
- Do I need ovarian suppression with this treatment?
- What dose and schedule will I follow?
- How often will I need blood tests?
- Which symptoms should I report urgently?
- Can I take my current medicines with Palbociclib?
- What are my options if Palbociclib stops working?
How CancerFax supports Palbociclib patients
CancerFax helps breast cancer patients and families understand their reports, weigh their options, and access the right treatment.
| Report review | Upload your biopsy, ER/PR/HER2, imaging, and biomarker reports — our team reviews them and explains what they mean for palbociclib and other breast cancer options. |
| Specialist connection | We connect patients with breast oncologists experienced in CDK4/6 inhibitor and endocrine therapy in India, China, and other centres. |
| Second opinion | If you are unsure about your regimen, or the cancer has progressed, CancerFax arranges an expert second opinion. |
| Access and cost navigation | We help check practical availability, branded versus generic options, and hospital pricing, and provide per-cycle cost estimates where possible. |
| Advanced and trial options | For patients considering newer targeted drugs, antibody-drug conjugates, or clinical trials after CDK4/6 inhibitor therapy, CancerFax helps explore appropriate options. |
Frequently asked questions about Palbociclib
Common questions from patients and caregivers
Palbociclib is a targeted therapy, not chemotherapy. It blocks two enzymes called CDK4 and CDK6 that help breast cancer cells divide, rather than broadly attacking all fast-dividing cells in the body. Because it works on a specific pathway, its side-effect pattern is different from standard chemotherapy. It is taken as an oral capsule or tablet at home and is almost always combined with hormone (endocrine) therapy.
Palbociclib is meant to control the cancer rather than cure it, so the goal is to slow or stop growth. Doctors usually check response with scans every two to three months, along with symptoms and blood tests. Some patients feel steady for many months or longer while the disease stays controlled. Your oncologist will tell you what your scans and reports mean for your own situation.
Palbociclib is processed by a liver enzyme called CYP3A, so some medicines can raise or lower its levels in the body. Certain antibiotics, antifungals, seizure medicines, and herbal products like St John's Wort can interfere with it, and grapefruit should be avoided. Always give your oncologist and pharmacist a full list of everything you take, including over-the-counter medicines and supplements, before and during treatment.
Generic palbociclib contains the same active ingredient at the same dose as branded Ibrance and is expected to work the same way when made to proper quality standards. In countries like India and China, approved generics have made the medicine more affordable for many patients. Always source it through a qualified oncologist and a reputable pharmacy. CancerFax can help you check legitimate access options.
The most common side effect of palbociclib is a drop in neutrophils, a type of white blood cell that fights infection. Blood counts are checked before each cycle, and more often in the first few months, so the dose can be paused or reduced if counts fall too low. This monitoring is routine and helps keep treatment safe, so try not to miss your blood tests.
If the cancer grows on palbociclib, your oncologist will usually repeat scans, review symptoms, and may order new biomarker testing such as ESR1 or PIK3CA on blood or tissue. The next step depends on what is found and your prior treatment, and can include a different endocrine therapy, a targeted drug such as a PI3K or AKT inhibitor, an antibody-drug conjugate, chemotherapy, or a clinical trial. A specialist second opinion can help identify the best option.
No. Palbociclib is approved only for advanced or metastatic HR-positive, HER2-negative breast cancer. Large trials of palbociclib added to hormone therapy after surgery for early breast cancer did not show a benefit, so it is not used in that setting. A different CDK4/6 inhibitor, abemaciclib, is the one used for selected high-risk early breast cancer. Your oncologist will choose the right drug for your stage.
Yes. Palbociclib is used in India and China for HR-positive, HER2-negative advanced breast cancer, and approved generic versions have improved affordability in both countries. Exact brand, formulation, and price vary by hospital, city, and pharmacy, so always ask for a written estimate. CancerFax can help you check practical availability, hospital options, and second-opinion pathways across India, China, and other centres.